As the conventional antirheumatic compounds do not halt disease progression in CND-RA, we hypothesize that these patients would potentially benefit from treatment strategies that target immune signaling that is essential for CD8+ cells, e.g. compounds that inhibit JAK-STAT signaling. The gene discussed is CD8A; the disease is rheumatoid arthritis.